Solid Biosciences (NASDAQ:SLDB) Earns "Market Outperform" Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Solid Biosciences (NASDAQ:SLDB - Free Report) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

Several other research firms have also recently weighed in on SLDB. Barclays cut their price objective on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Chardan Capital dropped their price objective on shares of Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, May 19th. HC Wainwright lifted their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Wedbush dropped their price objective on Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday, March 13th. Ten research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $14.90.

Solid Biosciences Stock Performance

NASDAQ:SLDB traded up $0.08 during trading hours on Friday, hitting $4.62. The stock had a trading volume of 1,819,697 shares, compared to its average volume of 1,127,612. Solid Biosciences has a one year low of $2.41 and a one year high of $10.37. The company has a market cap of $358.12 million, a price-to-earnings ratio of -1.52 and a beta of 2.22. The business's 50 day moving average is $3.13 and its 200-day moving average is $3.96.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). On average, sell-side analysts anticipate that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Institutional Trading of Solid Biosciences

A number of institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its holdings in Solid Biosciences by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock valued at $53,000 after purchasing an additional 2,986 shares during the period. Rhumbline Advisers boosted its holdings in Solid Biosciences by 10.5% in the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company's stock valued at $175,000 after purchasing an additional 4,161 shares during the period. Wellington Management Group LLP boosted its holdings in Solid Biosciences by 4.0% in the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock valued at $498,000 after purchasing an additional 4,747 shares during the period. Geode Capital Management LLC boosted its holdings in Solid Biosciences by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 509,802 shares of the company's stock valued at $2,040,000 after purchasing an additional 4,932 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Solid Biosciences by 10.6% in the 1st quarter. American Century Companies Inc. now owns 51,835 shares of the company's stock valued at $192,000 after purchasing an additional 4,978 shares during the period. Institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.